In 2007 it was discovered that the drug DCA (Dichloroacetate Sodium) induced the death of human breast, lung and brain cancer cells that were implanted into rats, while being non-toxic to healthy cells. DCA works by turning on the natural cell suicide system (called apoptosis) which is suppressed in cancerous cells, thus allowing them to die on their own. DCA also interferes with the cancer cell's use of glucose, starving the cell of energy. At the same time, it does not starve healthy cells in the body of glucose.
DCA research has accelerated in the last 2 years. The latest research shows that DCA also kills many types of cancer cells and can boost the cancer-killing effects of radiation. The first formal human cancer research using DCA was published in May 2010. It confirmed that DCA is an effective anti-cancer drug for treating glioblastoma patients (Metabolic Modulation of Glioblstoma with Dichloroacetate, Science Transltional Medicine, Vol 2, Issue 31).
Several publications demonstrated that DCA works in a variety of cancers. These include human studies, as well as case reports and lab studies (rat and in vitro). The cancer types studied so far are: colon, breast, prostate, ovaria, brain (neuroblastoma and glioblastoma), lung (carcinoid), uterus (cervix and endometrial), lymphoma (non-Hodgkin's) and cancer of unknown primary.
If you have any questions on DCA or would like to schedule a consultation, please call us at (941) 955-6220 and speak to a member of our expert staff.
The information on this site is for Educational Purposes Only and is not designed to diagnose, treat, mitigate, prevent or cure any health conditions.
The U.S. Food and Drug Administration has not evaluated statements about these health topics or any suggested product compositions.
Copyright © 2018 FLIMC - All Rights Reserved.